<div id="readability-page-1"><p><span>Mesa Laboratories (NASDAQ:MLAB - Get Free Report)</span> was downgraded by equities research analysts at StockNews.com from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report released on Wednesday.</p><div><p><span></span><span>Get <strong>Mesa Laboratories</strong> alerts:</span></p></div><p>Several other brokerages have also commented on MLAB. Wells Fargo &amp; Company started coverage on shares of Mesa Laboratories in a report on Tuesday, August 27th. They issued an &#34;underweight&#34; rating and a $120.00 price objective for the company. Evercore ISI lifted their price target on Mesa Laboratories from $120.00 to $160.00 and gave the company an &#34;outperform&#34; rating in a research report on Tuesday, October 1st.</p><p><b>Get Our Latest Analysis on Mesa Laboratories</b></p><h2>Mesa Laboratories Stock Down 5.5 %</h2><p>Shares of NASDAQ MLAB opened at $112.40 on Wednesday. The firm has a fifty day simple moving average of $124.09 and a two-hundred day simple moving average of $115.00. Mesa Laboratories has a 12 month low of $82.86 and a 12 month high of $141.17. The company has a current ratio of 1.94, a quick ratio of 1.37 and a debt-to-equity ratio of 1.38. The firm has a market capitalization of $608.08 million, a PE ratio of -2.47 and a beta of 0.87. </p><h2>Insider Buying and Selling at Mesa Laboratories</h2><p>In other news, CEO Gary M. Owens sold 2,518 shares of the business's stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $113.62, for a total value of $286,095.16. Following the sale, the chief executive officer now directly owns 45,888 shares of the company's stock, valued at $5,213,794.56. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, SVP Brian David Archbold sold 1,499 shares of Mesa Laboratories stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $125.00, for a total value of $187,375.00. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at this link. Also, CEO Gary M. Owens sold 2,518 shares of the stock in a transaction dated Monday, October 28th. The shares were sold at an average price of $113.62, for a total transaction of $286,095.16. Following the sale, the chief executive officer now directly owns 45,888 shares in the company, valued at $5,213,794.56. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own  4.40% of the company's stock. </p><h2>Institutional Inflows and Outflows</h2><p>Hedge funds and other institutional investors have recently made changes to their positions in the company. Meros Investment Management LP purchased a new position in  Mesa Laboratories in the 2nd quarter worth approximately $2,456,000.  Keeley Teton Advisors LLC bought a new stake in shares of  Mesa Laboratories in the 1st quarter worth $2,606,000.  Charles Schwab Investment Management Inc. raised its stake in shares of  Mesa Laboratories by 38.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 62,609 shares of the medical instruments supplier's stock worth $8,130,000 after purchasing an additional 17,450 shares during the last quarter.  Eagle Asset Management Inc. lifted its holdings in shares of  Mesa Laboratories by 10.9% during the third quarter. Eagle Asset Management Inc. now owns 165,955 shares of the medical instruments supplier's stock valued at $19,722,000 after purchasing an additional 16,293 shares in the last quarter.  Finally, Dimensional Fund Advisors LP boosted its position in shares of  Mesa Laboratories by 7.1% during the second quarter. Dimensional Fund Advisors LP now owns 131,891 shares of the medical instruments supplier's stock valued at $11,444,000 after buying an additional 8,722 shares during the last quarter. Institutional investors own  90.60% of the company's stock. </p><h2>Mesa Laboratories Company Profile</h2> (Get Free Report)<p>Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Mesa Laboratories</li><li>The 3 Best Fintech Stocks to Buy Now</li><li>Home Depot Stock: Targeting 12% in 2024 and 25% More in 2025</li><li>Procter &amp; Gamble <span>NYSE: PG<span></span></span> Pulls Back After Shaky Guidance</li><li>Is Tesla's Valuation a Bubble or Backed by Real Growth?</li><li>Energy and Oil Stocks Explained</li><li>Trucking Stocks Led the Pack Last Week: Can They Keep Rolling?</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><p>→ Top &#34;Sleeping Giant&#34; Crypto In The Market Now <span><span>(From Crypto 101 Media)</span> <span>(Ad)</span></span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDMzNQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDMzNQ"/></p><h2>Should you invest $1,000 in Mesa Laboratories right now?</h2><p>Before you consider Mesa Laboratories, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesa Laboratories wasn't on the list.</p><p>While Mesa Laboratories currently has a &#34;Hold&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

MLAB

<p>StockNews.com has downgraded Mesa Laboratories (NASDAQ:MLAB) from a "buy" to a "hold" rating. The stock opened at $40.40, down 5.5%. Other brokerages have also commented, with Wells Fargo issuing an "underweight" rating and Evercore ISI raising their price target. Insider trading includes CEO Gary M. Owens selling shares, reducing his stake. Institutional investors hold 90.60% of the company, with recent purchases from various funds. Mesa Laboratories specializes in life sciences tools and quality control products.</p>

Mesa Laboratories (NASDAQ:MLAB) Stock Rating Lowered by StockNews.com